Need help? Our team of experienced experts is here for you with full support.
AKA-200
Repotrectinib
Cat. No.
AKA-200
CAS No.
1802220-02-5
MF
C18H18FN5O2
MW
355.37
Repotrectinib is a potent ROS1 inhibitor.
Advanced Equipments & Extensive Production Expertise
Commercial Manufacturing
Stable Quality
Customization Supporting
Technical Data
Description
Storage and Shipping
References
Product Name
Repotrectinib
CAS No.
1802220-02-5
MF
C18H18FN5O2
MW
355.37
Specification
98%
Research Area
Oncology
Description
Repotrectinib is a potent ROS1 inhibitor. Packing: 10mg, 20mg, 50mg, 100mg, 500mg, 1g, 5g, 10g, 1kg Availability: API for research only, commercial supply only after the patent expires
Documents
Certificate of Analysis (COA), API specification, Safety Data Sheet (SDS/MSDS), evidence of GMP compliance, Stability data / Stability summary, etc.
Storage and Shipping
Store in a cool & dry place, keep away from strong light and heat.
References
[1]. Dayong Zhai, et al. Abstract 2132: The novel, rationally-designed, ALK/SRC inhibitor TPX-0005 overcomes multiple acquired resistance mechanisms to current ALK inhibitors. Cancer Research. July 2016.
[2]. Karachaliou N, et al. Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis. EBioMedicine. 2018 Mar;29:112-127.
[2]. Karachaliou N, et al. Common Co-activation of AXL and CDCP1 in EGFR-mutation-positive Non-smallcell Lung Cancer Associated With Poor Prognosis. EBioMedicine. 2018 Mar;29:112-127.
Disclaimer
This product is intended solely for scientific research or regulatory filing purposes. We do not provide products or services to individuals, please strictly comply with all applicable laws, regulations, and the committed use. Use for any other purpose is strictly prohibited.
Related Products
* Some statements have not been evaluated by national authorities. * Some products are not intended to diagnose, treat, cure, or prevent any disease. * For literature supporting, please contact us directly.